» Articles » PMID: 36839995

Automated Interlaboratory Comparison of Therapeutic Drug Monitoring Data and Its Use for Evaluation of Published Therapeutic Reference Ranges

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Feb 25
PMID 36839995
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic drug monitoring is a tool for optimising the pharmacological treatment of diseases where the therapeutic effect is difficult to measure or monitor. Therapeutic reference ranges and dose-effect relation are the main requirements for this drug titration tool. Defining and updating therapeutic reference ranges are difficult, and there is no standardised method for the calculation and clinical qualification of these. The study presents a basic model for validating and selecting routine laboratory data. The programmed algorithm was applied on data sets of antidepressants and antipsychotics from three public hospitals in Denmark. Therapeutic analytical ranges were compared with the published therapeutic reference ranges by the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) and in additional literature. For most of the drugs, the calculated therapeutic analytical ranges showed good concordance between the laboratories and to published therapeutic reference ranges. The exceptions were flupentixol, haloperidol, paroxetine, perphenazine, and venlafaxine + o-desmethyl-venlafaxine (total plasma concentration), where the range was considerably higher for the laboratory data, while the calculated range of desipramine, sertraline, ziprasidone, and zuclopenthixol was considerably lower. In most cases, we identified additional literature supporting our data, highlighting the need of a critical re-examination of current therapeutic reference ranges in Denmark. An automated approach can aid in the evaluation of current and future therapeutic reference ranges by providing additional information based on big data from multiple laboratories.

Citing Articles

The prevalence of off-label use and supratherapeutic blood levels of outpatient psychotropic medication in suicidal adolescents.

Hach I, Bertsch T, Nonell P Front Psychiatry. 2024; 14:1240681.

PMID: 38298931 PMC: 10827976. DOI: 10.3389/fpsyt.2023.1240681.

References
1.
VANDEL S, Vandel B, SANDOZ M, ALLERS G, Bechtel P, VOLMAT R . Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline. Eur J Clin Pharmacol. 1978; 14(3):185-90. DOI: 10.1007/BF02089958. View

2.
Kirschbaum K, Muller M, Malevani J, Mobascher A, Burchardt C, Piel M . Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2007; 9(3):212-8. DOI: 10.1080/15622970701361255. View

3.
Scherf-Clavel M, Hommers L, Wurst C, Stonawski S, Deckert J, Domschke K . Higher venlafaxine serum concentrations necessary for clinical improvement? Time to re-evaluate the therapeutic reference range of venlafaxine. J Psychopharmacol. 2020; 34(10):1105-1111. DOI: 10.1177/0269881120936509. View

4.
Fang J, Baker G, Silverstone P, Coutts R . Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell Mol Neurobiol. 1997; 17(2):227-33. PMC: 11560196. DOI: 10.1023/a:1026317929335. View

5.
Tveito M, Smith R, Molden E, Hoiseth G . Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. Eur J Clin Pharmacol. 2020; 77(2):215-221. DOI: 10.1007/s00228-020-03002-y. View